Immunome Inc.

Immunome Inc. (NASDAQ: IMME) is a biotechnology company committed to developing first-in-class and best-in-class targeted oncology therapies designed to improve outcomes for cancer patients. The company operates as a clinical-stage biopharmaceutical enterprise with expertise in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. More information about the company is available at www.immunome.com.

The company's pipeline includes three clinical-stage assets and three preclinical assets. Varegacestat, an oral gamma secretase inhibitor acquired from Ayala Pharmaceuticals, is under evaluation for the treatment of desmoid tumors and achieved positive Phase 3 RINGSIDE trial results in December 2025, with an anticipated new drug application submission planned for the second quarter of 2026. IM-1021 is a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate currently in Phase 1 trials, with observed objective responses in B-cell lymphoma patients. IM-3050 is a fibroblast activation protein-targeted radioligand therapy that received investigational new drug clearance in April 2025. The three preclinical assets—IM-1617, IM-1340, and IM-3050—are solid tumor antibody-drug conjugates with anticipated 2026 investigational new drug submissions.

A cornerstone of Immunome's strategy is HC74, a proprietary topoisomerase 1 inhibitor payload designed to address limitations of existing payloads by reducing efflux potential and increasing bystander activity. The company's discovery approach focuses on designing antibody-drug conjugates against novel or underexplored targets rather than pursuing the small number of highly prevalent targets that dominate the field. Through extensive screening of over 1,000 targets, the company has identified more than 40 targets evaluated in vitro and more than 15 targets evaluated in vivo.

Immunome was formed through strategic acquisitions and licensing agreements, including the acquisition of varegacestat and related assets from Ayala Pharmaceuticals in March 2024 and the acquisition of ROR1 antibody-drug conjugate assets from Zentalis Pharmaceuticals in October 2024. The company's leadership team comprises executives with prior experience in the design, development, and commercialization of cutting-edge targeted cancer therapies, including the first antibody-drug conjugates commercialized for Hodgkin and T-cell lymphoma, urothelial cancer, and cervical cancer.